Attention-deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders NPs will encounter. ADHD affects 6.4 million (11%) school-aged children 4 to 17 years old in the United States.1 The rate of ADHD diagnosis increased by 42% between 2003 and 2011.2 The average age at diagnosis is 7 years, and nearly 75% of patients are diagnosed before age 9 years.1 If a diagnosis is made earlier in life, the ADHD symptoms are more severe.1
Males tend to be diagnosed with ADHD at twice the rate of females, but females are most often diagnosed with a predominantly inattentive presentation.3 Females with ADHD have higher rates of comorbid conditions, including internalizing conditions (such as anxiety and depression) and externalizing conditions (such as oppositional defiant disorder and conduct disorder) when compared with females without ADHD.4
Black and Hispanic children are diagnosed and treated for ADHD at a significantly lower rate than White children, and these rates often persist through the 10th grade. This pattern could be due to underreporting symptoms in Black and Hispanic communities, which warrants more universal screening for ADHD symptoms. This difference is not thought to be due to overdiagnosis of White children.5
There are well-established lifespan trends for ADHD. In childhood, ADHD symptoms are more commonly identified with hyperactive and impulsive symptoms. As individuals age into adolescence and young adulthood, the symptoms of hyperactivity and impulsivity become less pronounced, but the symptoms of inattention persist and continue to cause impairment.6 Individuals who are diagnosed with ADHD still meet criteria in 60% to 85% of adolescents and approximately 50% of adults.7
ADHD rates worldwide affect 8% to 12% of the population.8 These worldwide data are supported by the strong hereditability of ADHD among all individuals. Twin studies from across the globe confirm that ADHD is inherited in nearly 80% of the offspring of parents with ADHD.9 ADHD also has one of the strongest genetic associations among all psychiatric conditions across the globe.9
Neurobiology and neurochemistry of ADHD
ADHD is a complex disorder that affects nearly all regions of the brain. The prefrontal cortex (PFC) is usually implicated in ADHD and is where executive functioning is housed. Executive functioning is the ability to plan and solve problems; it has been described as working memory, temporal information processing, and response inhibition. It predominates the hyperactive and impulsive symptoms of ADHD.10
The PFC malfunctions in children with ADHD, which accounts for hyperactive symptoms.6 Impulsive symptoms of ADHD appear to be related to the orbitofrontal cortex.6 Studies have also implicated the cerebellum and basal ganglia as being involved with symptoms of hyperactivity and impulsivity associated with ADHD.11
Inattention symptoms of ADHD have been described as problems with selective attention, sustained attention, and response precision. Cognitive flexibility impairment can account for both inattentive and hyperactive symptoms in ADHD.10,11 Impaired selective attention and sustained attention seen in ADHD have been found in the dorsal anterior midcingulate cortex and dorsal anterior cingulate cortex, using functional magnetic resonance imaging (fMRI) and neuropsychological testing.12 fMRI has also identified impairment with sustaining attention and smoothly shifting from one topic to the next (cognitive flexibility) within the dorsolateral PFC.
Dopamine has long been implicated in ADHD and continues to be a target of medication therapy for ADHD.13 Dopamine is primarily synthesized in the midbrain (in the substantia nigra) and is transported to various parts of the brain to include the PFC, caudate, putamen, nucleus accumbens, amygdala, hippocampus, and cerebral cortex. Dopamine D1 and D2 receptors are important for working memory and cognitive flexibility, respectively.9
Gamma-Aminobutyric acid is a significant neurotransmitter in ADHD and is responsible for nearly 70% of all inhibition of the dopamine signal, which results in downstream effects of the entire dopamine system.10 Norepinephrine in the locus coeruleus also plays a significant role in sustained attention symptoms in ADHD.9 Cognitive flexibility symptoms in ADHD are linked to acetylcholine in the PFC along with D2 receptors. Serotonin in the basal ganglia and PFC appear to influence how an individual can delay rewards, which is grossly impaired in ADHD.10,11 Skilled NPs will use this information when assessing and treating ADHD in children, adolescents, and young adults.
Assessment of ADHD
ADHD is a clinical diagnosis characterized by three symptom clusters of inattention, hyperactivity, and impulsivity. Individuals who have ADHD are identified as having a predominate presentation in either inattention, hyperactivity and impulsivity, or both.3,14 Primary care providers and pediatricians diagnose approximately 50% of children with ADHD, psychiatrists and psychologists make the diagnosis for the other 50%.14
Given the recognized shortage of psychiatrists in the United States, the integration of mental health into primary care is beneficial for children throughout young adulthood, so the ability to assess, diagnosis, and treat ADHD in primary care practices is essential for NPs.15
Individuals of all ages should undergo a comprehensive assessment to determine an accurate diagnosis of ADHD and assess for the presence of possible risk factors for ADHD or the presence of comorbid conditions.16,17 The use of behavioral screening tools provides objectivity to the assessment and should be used as part of the evaluation.16
NPs should initiate an evaluation for ADHD for children who present with academic or behavioral conditions that interfere with functioning and have symptoms of inattention, hyperactivity, or impulsivity during the ages of 4 to 18 years.16 The diagnosis of ADHD should follow established guidelines in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), including the requirements for symptom documentation over time, in more than one major setting, and by one or more parent, guardian, teacher, or another adult who works closely with the child.3,16 Adolescents with ADHD symptoms may be assessed during adolescence and considered positive if symptoms are present between the ages of 7 to 12 years.16
The assessment should be comprehensive and identify the chief complaint, symptoms of ADHD, academic problems, behavioral conditions, and the level of functional impairment.18 An extensive medical history should be obtained to identify the presence of risk factors or comorbid conditions (see Comorbid conditions and risk factors associated with ADHD).19 A review of systems with a focus on diet, sleep, activity level, and elimination may reveal dietary patterns that may not support optimal health or elimination problems, such as enuresis or encopresis. Delayed sleep onset or variable sleep routines may affect overall health.
Because ADHD has a strong genetic propensity, it is important to obtain a complete family medical and psychiatric history.16,17 Exposure to toxic stressors such as child maltreatment, violence, and family and community stressors should be identified to incorporate knowledge of them into any treatment plan. Parental or child adverse events should also be assessed.19 Parenting practices and how parents address the child's behavioral concerns should be identified.20
A comprehensive social history, including an understanding of the child's environment and how ADHD is affecting family members, should be obtained. How the child is functioning in the home, school, and community will provide the NP with insight into the severity of ADHD symptoms.16
A complete physical exam, including a neurologic exam, should be obtained for all children being evaluated for an ADHD diagnosis.16,18 The NP should examine the child for any dysmorphic features to rule out a genetic disorder.18 Growth parameters and body proportion should be evaluated. There is no evidence for using lab tests or imaging studies in diagnosing children with ADHD.
The next step in the assessment is to obtain symptom documentation over time and in more than one major setting (for example, home and preschool/school). The National Institute for Children's Health Quality (NICHQ) developed the Vanderbilt Assessment Scales for initial evaluation and follow-up of ADHD in preschool and school-age children (between ages 6 to 12 years). The scales are available at no cost through the NICHQ (www.nichq.org/sites/default/files/resource-file/NICHQ_Vanderbilt_Assessment_Scales_0.pdf).21
The scales also screen for coexisting conditions (conduct disorder, oppositional-defiant disorder, anxiety, depression) and allow the NP to validate and differentiate ADHD presentations. These presentations are based on the DSM-5 criteria and predominant symptom patterns for the past 6 months, including combined presentation, predominantly inattentive presentation, and predominantly hyperactive/impulsive presentation. The Conner's Rating Scale-Revised may be used for ADHD assessment and is preferred in some practices; it is validated for children ages 6 to 17 years for teacher and parent forms and 8 to 17 years for self-report forms.22 A list of other rating scales and checklists to use in the evaluation of children through adulthood are available from the American Academy of Pediatrics (AAP).22
In addition to obtaining behavior rating scales, the NP should ask to see report cards and samples of the child's schoolwork; any formal testing performed by school personnel; a description of the child's behavior in the classroom; the child's learning patterns; how the symptoms affect the child's progress at school; ways the teacher has adapted the classroom program to help the child; and whether other conditions contribute to or affect the symptoms.23 Once a comprehensive history and physical exam have been performed, the NP should formulate a diagnosis.
When interviewing adolescents or young adults who present for a possible diagnosis of ADHD, the NP should perform a comprehensive history and may use the Home Education/Employment, Eating, Activities, Drugs and Alcohol, Sexuality, Suicide and Depression, Safety (HEEADSSS) interview.24 Obtaining a history regarding alcohol use or a possible substance use disorder should be a priority, and the possibility that the individual may be interested in obtaining stimulants for diversion should be considered.
Clinical practice suggests pornography viewing or excessive gaming may be occurring and should also be included as part of the assessment. Adolescents or young adults who have ADHD continue to have impairment in executive functioning or regulation in self-directed actions to choose, enact, and sustain actions across time toward a goal.25 This manifests as worse driving records compared with peers of a similar age, with 400% higher rates of speeding citations and crashes than individuals without ADHD.26 Those taking lisdexamfetamine dimesylate stopped on average 9.1% faster than those taking placebo, which is meaningful because they were measured driving 45 to 65 mph.26 Adolescents with ADHD who drive while taking medication to treat the disorder have significantly lower rates of accidents and better driving performance compared with those who are not taking ADHD medications. It is estimated that over 22% of motor vehicle accidents of individuals with ADHD could have been avoided if they were taking ADHD medications.26,27
Treatment of ADHD involves psychosocial or behavioral management, modifications to the school program, and medication.28 NPs should educate families that ADHD is classified as a neurodevelopmental disorder with underlying biologic and neurologic mechanisms requiring chronic care, and the NP should reassure families that the concepts related to a patient-centered medical home model will be implemented in caring for the child.16 Parents should be informed that the child's ADHD behavior is not intentional, and behavioral change will need to occur with the family to make accommodations and support the child. Recommendations for treatment will vary depending on the child's age.
For preschool-aged children (ages 4 to 5 years), parent- or teacher-administered behavioral intervention should be the first line of treatment; medication (methylphenidate) may be considered if first-line treatments are not available or insufficient.16 For children ages 6 to 11 years, the combination of medication and behavioral interventions have the best outcome.16 For adolescents (ages 12 to 18 years), an FDA-approved medication should be prescribed, preferably along with behavior therapy.16
Many individuals with ADHD have negative interactions with family members, friends, and teachers, and both sides often feel distressed or worried about the behavior. Behavior therapy including behavioral parent training, social skills training, behavioral peer interventions, classroom behavioral management, or parent/family education can help mitigate the effects ADHD has on the child.28,29 Parent training recognizes that ADHD affects an entire family, and behavioral therapy involving all members of the household may restore balance in effective child behavior management.
Evidence-based parenting programs include New Forest Parenting Programme, Positive Parenting Program, The Incredible Years series, and Parent Child Interaction Therapy.28,29 Information can be provided either by hardcopy or electronically to parents in regard to evidence-based information on ADHD symptoms and treatment options (see ADHD provider resources).
If academic or behavioral issues are present in the child's school, parents may request an evaluation from the school's multidisciplinary evaluation team.30 Parents must sign permission forms before the evaluation process starts. A comprehensive evaluation should be done within 60 days but may vary from state to state.30 If the child qualifies for special education services, an individual education plan can be developed. If the child does not meet criteria for special education, a Section 504 Service Plan may be developed, which designates reasonable accommodations in the educational program and related aids and services if deemed necessary (for example, occupational or physical therapy).
Examples of common accommodations include seating at the front of the classroom, supplement verbal instructions with visual or written instructions, trackers/reminders for homework, a schedule, organized teacher assistance, modified test delivery, extended test time, assistance with long-term projects, tailored homework assignments, and/or systematic rewards and consequences.30
The use of medication has been shown to be effective in more than 70% of individuals with ADHD.31 When initiating psychopharmacologic therapy for ADHD stimulant medication should be used as first-line treatment.16,17 The Multimodal Treatment of ADHD trials showed improvement in symptoms of inattention, hyperactivity, impulsivity, and improvement in disruptive behaviors, with some improvements in academic functioning and peer relations with stimulant medications.32-35
Methylphenidate-based stimulants work by blocking the dopamine-active transport (DAT) and norepinephrine-active transport (NET), thereby increasing dopamine and norepinephrine in the synapses.6 Amphetamine-based stimulants work similarly at lower doses than methylphenidate. At higher doses, amphetamine-based medications reverse the flow to the DAT and NET. Because of this, amphetamine-based stimulants are considered twice as potent as methylphenidate-based stimulants.6
Before prescribing stimulants, recommendations for screening include obtaining a targeted cardiac history, which includes patient history of previously detected cardiac disease, palpitations, syncope, or seizures; a family history of sudden death in children or young adults; hypertrophic cardiomyopathy; and long QT syndrome. In addition, a careful cardiac exam and referral for an ECG or a cardiologist for patients with suspected heart disease or identified risk factors for sudden death should be considered.36
There are several formulations of methylphenidate and amphetamine-based medications. All stimulants are thought to be equally effective, but starting with methylphenidate is often recommended with evidence that amphetamines may have a greater risk of adverse reactions.37 The FDA-approved minimum age for most stimulants is 6 years, but immediate-release dextroamphetamine and mixed amphetamine salts have both been approved starting at age 3 years.16 Some general principles in prescribing include starting with a low dose and titrating upward (“start low, go slow”) to ensure that the child receives the maximum benefit with the fewest adverse reactions.16 Titration should occur at weekly or every other week.
Atomoxetine, extended-release guanfacine, and extended-release clonidine can be used as second- and third-line medications and are useful alternatives to stimulants in children with comorbid conditions or substance use disorders.38 Bupropion, an atypical antidepressant that increases the transmission of dopamine and norepinephrine by blocking the reuptake of both neurochemicals, is as effective as methylphenidate in treating ADHD symptoms from age 6 years and up.6,39,40 In practice, bupropion is FDA off-label for ADHD, it does not have dosage recommendations for pediatric patients with ADHD, and the best effects are seen in patients with ADHD and depressive symptoms as well as those who may have misused a controlled substance.39,40
Bupropion is generally well tolerated, but there is a black box warning related to suicidal thoughts and behaviors for use in pediatric patients.40 Adverse reactions of bupropion include nausea, dry mouth, anorexia, headache, insomnia, tremor, anxiety, weight loss, and increased BP.41 Modafinil is a dopamine agonist that has evidence of treating ADHD from age 6 years and older.40 Like bupropion, modafinil is considered a nonstimulant option and is FDA off-label for ADHD that is usually prescribed as a fourth-line treatment option for ADHD. Modafinil is generally well tolerated, and the effects can be seen quickly. Dosing is not well established in pediatric populations.40 Adverse reactions of modafinil include dyspepsia, nausea, diarrhea, headache, anxiety, and insomnia.
There is a potential for linear growth impairment with psychostimulant medications, so children should be monitored carefully for height and weight.43 Challenges with medication management include the extended-release medication not lasting long, as some patients are fast CYP450 metabolizers, so these cases may need an immediate-release stimulant prescribed as an afternoon dose (see ADHD medications and adverse reactions).
If none of the agents routinely used to treat ADHD are effective, the NP should undertake a careful review of the diagnosis and consider behavior therapy for ADHD treatment and referral of the patient to a psychiatrist or psychiatric mental health NP.16 Parents require frequent consultation for concerns when starting medication, so practices need to arrange for availability for questions and communication as well as frequent follow-up.
The role of the NP is to monitor children, adolescents, and young adults with ADHD who are treated with medication regularly, monitoring their height, weight, BP, and pulse, and identify adverse reactions. Periodic assessments should determine if there is a continued need for treatment or if symptoms have remitted, and treatment should continue if symptoms remain present and cause impairment.16 The NP should monitor school performance, child and family functioning, and make appropriate referrals for diagnosis and treatment. Early and effective identification and treatment of ADHD prevents long-term consequences and can lead to healthy and productive lifestyles for affected patients.
1. Visser SN, Zablotsky B, Holbrook JR, Danielson ML, Bitsko RH. Diagnostic experiences of children with attention-deficit/hyperactivity disorder. Natl Health Stat Report
2. Centers for Disease Control and Prevention. How children are diagnosed with attention-deficit/hyperactivity disorder. 2016. www.cdc.gov/ncbddd/adhd/features/how-us-children-diagnosed.html
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders
. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
4. Tung I, Li JJ, Meza JI, et al. Patterns of comorbidity among girls with ADHD
: a meta-analysis. Pediatrics
5. Coker TR, Elliott MN, Toomey SL, et al. Racial and ethnic disparities in ADHD
diagnosis and treatment. Pediatrics
6. Stahl S. Attention deficit hyperactivity disorder and its treatment. In: Stahl's EssentialPsychopharmacology: Neuroscientific Basis and Practical Applications
. Cambridge, United Kingdom: Cambridge University Press; 2013:471–502.
7. Shaw M, Hodgkins P, Caci H, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med
8. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics
9. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry
10. Mueller A, Hong DS, Shepard S, Moore T. Linking ADHD
to the neural circuitry of attention. Trends Cogn Sci
11. Cortese S. The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD
): what every clinician should know. Eur J Paediatr Neurol
12. Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K. Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry
13. Gonon F. The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining. Trends Neurosci
14. Centers for Disease Control and Prevention. Key findings: trends in the parent-report of health care provider-diagnosis and medication treatment for ADHD
: United States, 2003-2011. 2017. www.cdc.gov/ncbddd/adhd/features/key-findings-adhd72013.html
15. Tyler ET, Hulkower RL, Kaminski JW. Behavioral health integration in pediatric primary care considerations and opportunities for policymakers, planners, and providers. 2017. www.milbank.org/publications/behavioral-health-integration-in-pediatric-primary-care-considerations-and-opportunities-for-policymakers-planners-and-providers
16. Wolraich M, Brown L, Brown RT, et al. Subcommittee on attention-deficit/hyperactivity disorder; Steering Committee on quality improvement and management. ADHD
: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics
17. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry
18. French WP. Assessment and treatment of attention-deficit/hyperactivity disorder: part 1. Pediatr Ann
19. Substance Abuse and Mental Health Services Administration. Co-occurring disorders. 2016. www.samhsa.gov/disorders/co-occurring
20. Schoenfelder EN, Sasser T. Skills versus pills: psychosocial treatments for ADHD
in childhood and adolescence. Pediatr Ann
21. National Institute for Children's Health Quality. NICHQ Vanderbilt Assessment Scales. 2002. www.nichq.org/childrens-health/adhd/resources/vanderbilt-assessment-scales
22. American Academy of Pediatrics. Mental Health Screening and Assessment Tools for Primary Care. 2012. www.aap.org/en-us/advocacy-and-policy/aap-health-initiatives/Mental-Health/Documents/MH_ScreeningChart.pdf
23. Children and Adults with Attention-Deficit/Hyperactivity Disorder (ADHD
). Comprehensive assessment. 2017. www.chadd.org/understanding-adhd/for-parents-caregivers/comprehensive-assessment.aspx
25. Barkley RA. The important role of executive functioning and self-regulation in ADHD
: fact sheet. 2016. www.russellbarkley.org/factsheets/ADHD_EF_and_SR.pdf
26. Biederman J, Fried R, Hammerness P, et al. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD
: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res
27. Chang Z, Quinn PD, Hur K, et al. Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry
28. Evans SW, Owens JS, Bunford N. Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder. J Clin Child Adolesc Psychol
29. Ryan-Krause P. Preschoolers with ADHD
and disruptive behavior disorder. J Nurse Pract
30. Children and Adults with Attention-Deficit/Hyperactivity Disorder (ADHD
). Individuals with Disabilities Education Act. 2017. www.chadd.org/Understanding-ADHD/For-Parents-Caregivers/Education/Individuals-with-Disabilities-Education-Act.aspx
31. Jensen PS, Arnold LE, Swanson JM, et al. 3-Year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry
32. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH multimodal treatment study of ADHD
(MTA): implications and applications for primary care providers. J Dev Behav Pediatr
33. Molina BS, Hinshaw SP, Swanson JM, et al; MTA Cooperative Group. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD
in a multisite study. J Am Acad Child Adolesc Psychiatry
34. MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD
: a 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD
. Arch Gen Psychiatry
35. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD
follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics
36. Hamilton R, Gray C, Bélanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry
37. Fischer B, Herberholz N. Practical guide to the management of ADHD
. Paediatr Child Health
38. Southammakosane C, Schmitz K. Pediatric psychopharmacology
for treatment of ADHD
, depression, and anxiety. Pediatrics
39. Cantwell DP. ADHD
through the life span: the role of bupropion in treatment. J Clin Psychiatry
. 1998;59(suppl 4):92–94.
40. Wang SM, Han C, Lee SJ, et al. Modafinil for the treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Psychiatr Res
41. Ng QX. A systematic review of the use of bupropion for attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol
42. Stahl S. Prescribers Guide: Stahl's Psychopharmacology
. 5th ed. Cambridge, UK: Cambridge University Press; 2014.
43. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry